Tapsi Kumar, PhD (@TapsiKS) header
Tapsi Kumar, PhD (@TapsiKS) profile picture

BMS | ExChair - Scholarships @Awis_Houston | PHD @MDAndersonNews. Single cell genomics | Computational Biologist | Oncology. Crazy animal (-reptile) lover.

Cambridge, MA
Joined March 2014
Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)Photo by Tapsi Kumar, PhD (@TapsiKS)
Tapsi Kumar, PhD retweeted
Hallmarks of colorectal cancer subtypes👇 nature.com/articles/s41568-0… (Origins and heterogeneity of colorectal cancer)
119
2
393
23,307
Tapsi Kumar, PhD retweeted
Lymph node-targeted, mKRAS-specific amphiphile vaccine in #PancreaticCancer: the randomized phase 2 AMPLIFY-7P trial (@ElicioTx) nature.com/articles/s41591-0… Most important panel: in post surgical setting ctDNA positivity is pivotal driver of disease free survival, agnostic to vaccine
2
23
79
5,813
Tapsi Kumar, PhD retweeted
Here the 50+ ADCs that will be discussed at #ESMO26 next week, divided by payload class and target. B7-H3 TOPO1i leads, with 7 different ADCs! (Note: TiP and ePoster not included)
Only 2 weeks until the @myESMO 2026 Congress in Madrid! For ADCs: ▪️ 210+ regular abstracts and 23 Late-Breaking Abstracts (LBAs) accepted ▪️ 50+ talks, 120+ posters, and 60+ ePosters 👇👇 Here the list of the 14 ADCs being presented for the first time at #ESMO26!
5
60
1
175
16,418
Tapsi Kumar, PhD retweeted
ADC drug development is accelerating. But is biomarker science keeping pace? Nearly 50% of ADC trials require no biomarker, while most that do still rely on conventional IHC. In our new @NatRevClinOncol review published just in time pre-#ESMO26, we propose a modular framework to bridge this gap - moving beyond target expression to the multiple biological determinants of ADC efficacy and toxicity. Proud to lead this international effort with @BarbaraPistill2 @nedmcnamee @rreddel @VivekSubbiah and colleagues. 🔗: nature.com/articles/s41571-0…
4
28
1
85
11,986
Tapsi Kumar, PhD retweeted
An AI model trained from routine electronic health record data of 3.7 million individuals predicted cancer 1 year before clinical onset, no less promoted accuracy in detection, staging, treatment response, and prognosis cell.com/cell/fulltext/S0092…
19
173
12
571
104,864
Tapsi Kumar, PhD retweeted
Iza-Bren is very effective (not only in TNBC) but its profile is also very chemo-like. What’s the targeted contribution vs non-specific uptake? Iza-Bren half-life is ~1 day! What’s the correlation with EGFR expression? HER3 expression? Co-expression of both EGFR and HER3?
Impressive results from a phase 3 trial of Iza-Bren (anti-HER3/EGFR TOPO1 ADC) vs chemo in pretreated mTNBC, with improvement in PFS and OS. High rate of hematologic toxicities, including 5% febrile neutropenia. Phase 3 ongoing to confirm these results in a global population.
4
15
1
44
13,710
Tapsi Kumar, PhD retweeted
ビッグニュースが舞い込んできました! FDAでHER2陽性早期乳がんに対するエンハーツ(トラスツズマブ デルクステカン)が承認されました。 しかも、DB-11試験に基づく術前ハイリスク集団と、DB-05試験に基づく術後残存病変を有する集団の、両方に対して一気に適応されます。 同じように、日本での承認が待たれます。果たして術前も同時に承認されるのかがポイントになります。 fda.gov/drugs/resources-info…
Since the first phase 1 trial of T-DXd, it was clear that this drug could be transformative when taken to the curative setting. Today, the FDA approved T-DXd for the neoadjuvant or adjuvant treatment of HER2+ eBC, marking a major advancement in the field. fda.gov/drugs/resources-info…
2
36
1
159
21,465
Tapsi Kumar, PhD retweeted
A study in Nature reveals that tumour microenvironments can be decomposed into spatially organized multicellular ecosystems that can be accessed non-invasively via liquid biopsy and used to profile individual cancers and target treatments. go.nature.com/4wkkdnC
42
5
184
29,837
Tapsi Kumar, PhD retweeted
If you're serious about AI engineering (in 2026), then learn these 13 concepts: 1 How Vector Database Works → newsletter.systemdesign.one/… 2 How RAG Works → newsletter.systemdesign.one/… 3 Design Personal Chat Assistant → newsletter.systemdesign.one/… 4 LLM Concepts - A Deep Dive → newsletter.systemdesign.one/… 5 How to Design an AI Agent → newsletter.systemdesign.one/… 6 What is Reinforcement Learning → newsletter.systemdesign.one/… 7 LLM Evals 101 → newsletter.systemdesign.one/… 8 Context Engineering 101 → newsletter.systemdesign.one/… 9 AI Coding Workflow 101 → newsletter.systemdesign.one/… 10 Agentic Patterns, Simply Explained → newsletter.systemdesign.one/… 11 How AI Agents Work → newsletter.systemdesign.one/… 12 Multi-Agent Architectures, Clearly Explained → newsletter.systemdesign.one/… 13 How MCP Works → newsletter.systemdesign.one/… What else should make this list? === 👋 PS - Want my System Design Playbook (for Free)? Join my newsletter with 200K+ software engineers now: → newsletter.systemdesign.one/… === 💾 Save now & repost to help others learn AI engineering. 👤 Follow @systemdesignone + turn on notifications.
31
243
4
939
60,511
Tapsi Kumar, PhD retweeted
🫁 MTAP deletions in NSCLC and EGFR. MTAP del in 10% (n=4926). In stage IV, 83% co-occurred with drivers; EGFR in 48%. Shorter time to osimertinib discontinuation (19.0 vs 24.9 mo; HR 1.8; p=0.01). No significant OS difference. Acquired MTAP del at resistance in 13%. Signal of activity with PRMT5 inhibition (BMS-986504). 📖 @JTOonline DOI 👉🏻 doi.org/10.1016/j.jtho.2025.… #CánCare #NSCLC #EGFR #biomarkers #targetedtherapy #lcsm
29
1
66
8,762
Tapsi Kumar, PhD retweeted
Claude can now teach your kids any school subject like a $100/hour private tutor from Khan Academy. For free. Here are 12 prompts that explain math, science, history, and English at any grade level in minutes: (Save this before it disappears)
46
348
11
2,069
261,170
Tapsi Kumar, PhD retweeted
What a time to be alive when I have to choose between attending Brian Wolpin’s talk on Daraxonrasib + chemo in 1st line #PancreaticCancer OR @RevMedicines talk on their preclinical asset RM-055 that overcomes KRAS inhibitor resistance, BOTH at the exact same time! #AACR26
5
15
2
112
8,430
🔷Human Immune Cell Marker Guide 🩸🩸 #cellsignaling
70
273
12,898
Tapsi Kumar, PhD retweeted
Cancer immunotherapy keeps revving up. Now onto a 3rd generation of T cell engagers sciencedirect.com/science/ar…
2
72
1
275
22,419
Tapsi Kumar, PhD retweeted
More than 430 abstracts on ADCs at #AACR26! ⬆️ Largely dominated by TOPO1i ADCs and bispecific ADCs ↗️ Dual payload ADCs are growing (36 abstracts) ↘️ Degrader Antibody Conjugates (DACs) not so much (12 abstracts) ⬇️ Limited novel ADC payload classes (<15 abstracts)
9
34
1
139
13,971
Tapsi Kumar, PhD retweeted
This 2 hour Stanford lecture shows exactly how Stanford trains it's engineers to build AI systems. It's more practical than every Claude tutorial & prompting threads you've seen. Bookmark & give it 2 hours, no matter what. It'll be the most productive thing you do this weekend.
159
1,859
38
13,403
1,694,759
Tapsi Kumar, PhD retweeted
Claude Chat vs Cowork vs Code Tab vs Code CLI — what's actually different? I used Claude Code to fact-checked every feature against official Anthropic docs and put together this comparison table.
2
5
1
19
2,266
Tapsi Kumar, PhD retweeted
BREAKING: AI can now analyze any stock like a Wall Street analyst (for free). Here are 10 insane Claude prompts that replace $2,000/month Bloomberg terminals (Save for later)
12
76
3
483
72,405